Wyeth improves the lives of millions of people with an array of outstanding
products. Wyeth prescription products cover a wide range of conditions. Many of
these products are leaders in their individual therapeutic class.
Women's Health Care
Wyeth has been the leader in women's health care with its oral contraceptives
and post-menopausal hormone drugs for over 60 years. Wyeth continues to set the
pace in women's health care by developing new medications with the potential to
improve the health of women around the world.
Wyeth demonstrated its commitment to women's health issues by forming the
Women's Health Research Institute®
in 1993. The Women's Health Research Institute-the only institute in the
pharmaceutical industry dedicated solely to research in women's health-focuses
on the identification and development of new products. The Institute cooperates
with major professional and public organizations to encourage continuing
emphasis on health care issues that uniquely affect women.
Wyeth is currently doing research on several products intended to improve the
quality of women's lives. Products include a low-dose continuous contraceptive,
a non-hormonal therapy for the relief of menopausal hot flashes, and a new
therapy for the prevention and treatment of postmenopausal osteoporosis. Wyeth
has already introduced new low dose versions of its postmenopausal hormone
therapy products.
Return to Top
Neuroscience
Leading the way in the fight against central nervous system disabilities, Wyeth
has produced novel treatments for depression and anxiety. Wyeth researchers are
looking at small molecules, vaccines and biotechnology to develop treatments
targeted for many different central nervous system disorders. Current
neuroscience research at Wyeth includes the development of new treatments for
Alzheimer's disease, depression, anxiety, panic disorder, and schizophrenia.
Return to Top
Vaccines and Infectious Disease
The vaccines and infectious diseases franchises of Wyeth have and continue to
produce some of the most innovative products in the health care arena,
including the world's first vaccine against pneumococcal meningitis. Our
mission is to reduce the number of illnesses and deaths caused by bacterial and
viral infections and to address the growing problem of bacterial resistance to
existing antibiotic treatments. We are especially proud of the impact our
vaccines and antibiotics continue to have on the future of the world's
children.
Return to Top
Musculoskeletal Disorders
Wyeth develops important new therapies for patients with painful and often
debilitating joint and bone disease. Our products include treatments for
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile
rheumatoid arthritis that help patients lead more active lives. Wyeth is also a
leader in the osteoarthritis treatment market. Wyeth researchers are currently
investigating new treatments to promote bone and tissue repair.
Return to Top
Hemophilia and Bleeding Disorders
Since the 1980s, Wyeth has been a world leader in the search for new treatments
for hemophilia, a rare but serious bleeding disorder. Our commitment and
significant investment in recombinant DNA technology have led to important
medical advances in the treatment of these potentially debilitating diseases to
help individuals with hemophilia lead normal active lives. Wyeth has used
recombinant technology to produce factor products without using human plasma as
a starting material, which reduces the risk of human blood-borne viruses. At
Wyeth, we seek to improve the future for the hemophilia community, and this
includes partnering with other organizations to find a cure for hemophilia and
to support hemophilia patients. The World Federation of Hemophilia (WFH)
established a twinning program in 1994 to help improve the lives of people with
hemophilia in under-developed countries. Wyeth has been sponsoring the twinning
program for more than six years. In addition, Canada sponsors more twinning
centres than any other participating country.
Return to Top
Immunology
Wyeth's work in immunology focuses on producing novel immunosuppressant for
organ transplantation to reduce the incidence of organ rejection. Our work in
immunology has generated treatments for organ transplantation for the reduction
of organ rejection. Our efforts in cancer treatments include chemotherapy
agents for acute myeloid leukemia-a rapidly progressing cancer of the blood-and
a platelet growth promoter to help patients after chemotherapy. Wyeth currently
has several promising new cancer treatment drugs in clinical trials, including
treatments for kidney cell cancer, breast cancer, and mantle cell lymphoma.
Return to Top
Oncology
Our efforts in cancer treatments include chemotherapy agents for acute myeloid
leukemia-a rapidly progressing cancer of the blood-and a platelet growth
promoter to help patients after chemotherapy. Wyeth currently has several
promising new cancer treatment drugs in clinical trials, including treatments
for kidney cell cancer, breast cancer, and mantle cell lymphoma.
Return to Top
Skin Disease
Psoriasis is an incurable skin condition that affects about 2% of the world's
population and causes significant physical disability and mental stress. With
psoriasis, the immune system malfunctions, which causes skin cells to multiply
too quickly, causing inflamed, scaly patches called plaques that itch, crack,
and bleed. Until recently, there were few treatments that effectively managed
psoriasis.
Return to Top
Wyeth Animal Health
As a world leader in animal health, Wyeth Animal Health offers a broad range of
biological and pharmaceutical products for the companion animal, equine,
livestock, swine, and poultry industries.
Return to Top
Français
